Understand the source comparison
SS-31 for Anti-Aging Research Evidence: Comparison
Aged Mice (Lifespan Extension) Median survival time +11–14% median lifespan, +18% maximum lifespan in females 20 months–death Initiated late in life (20 months); earlier intervention outcomes unknown Heart Failure Patients (EMBRACE-STEMI) Infarct size reductio
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Aged Mice (Lifespan Extension)
- Median survival time
- +11–14% median lifespan, +18% maximum lifespan in females
- 20 months–death
- Initiated late in life (20 months); earlier intervention outcomes unknown
- Heart Failure Patients (EMBRACE-STEMI)
- Infarct size reduction (MRI)
- No significant reduction in primary endpoint; improved LVEF in anterior MI subset
- Single dose pre-PCI
- Single-dose design limits sustained benefit assessment
- Aged Rat Muscle (Insulin Resistance)
- Glucose uptake and ATP recovery
- +37% glucose uptake, −29% PCr recovery time vs aged controls
- 8 weeks continuous
- Effects reversed fully within 4 weeks of stopping treatment
- Cardiolipin Peroxidation (Ex Vivo)
- Cardiolipin oxidation and cristae density
- −68% cardiolipin peroxidation, cristae density restored to 89% of young controls
- Acute treatment
- In vitro model; translation to in vivo aging unknown